Testing nerandomilast for children with lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and under 18 years old
- Have lung scarring (fibrosing ILD) confirmed by a special CT scan within the past year
- If age 6 or older, have a lung function test (FVC) that is at least 25% of predicted normal
- Show signs that the lung disease is getting worse, such as a drop in lung function, more scarring, or needing more oxygen
- Not have taken this drug (nerandomilast) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Hear when a new Fibrosing Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.